Results 21 to 30 of about 5,637 (227)
Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents [PDF]
Journal of Infectious Diseases, 2017 , Nancie Archin, Archin Nancie M
exaly +2 more sources
Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA. [PDF]
Biol Open, 2020 Infection of HIV-1 remains incurable because long-lived, latently-infected cells persist during prolonged antiretroviral therapy. Attempts to pharmacologically reactivate and purge the latent reservoir with latency reactivating agents (LRAs) such as protein kinase C (PKC) agonists (e.g. ingenol A) or histone deacetylase (HDAC) inhibitors (e.g.
Taylor JP +4 more
europepmc +5 more sources
Novel Triazolopyridine-Based BRD4 Inhibitors as Potent HIV-1 Latency Reversing Agents [PDF]
ACS Medicinal Chemistry LettersZhiyu Li, Xun Li, Tian Renrong
exaly +2 more sources
NSC95397 Is a Novel HIV-1 Latency-Reversing Agent
Viruses, 2023 The latent viral reservoir represents one of the major barriers to curing HIV-1. Focus on the “kick and kill” (also called “shock and kill”) approach, in which virus expression is reactivated, and then cells producing virus are selectively depleted, has led to the discovery of many latency-reversing agents (LRAs) that have furthered our understanding ...
Randilea Nichols Doyle +5 more
openaire +6 more sources
Novel Latency Reversal Agents for HIV-1 Cure. [PDF]
Annu Rev Med, 2018 Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate ...
Spivak AM, Planelles V.
europepmc +4 more sources
Optimal Control of an HIV Model with Gene Therapy and Latency Reversing Agents
Mathematical and Computational Applications, 2021 In this paper, we study the dynamics of HIV under gene therapy and latency reversing agents. While previous works modeled either the use of gene therapy or latency reversing agents, we consider the effects of a combination treatment strategy.
Zachary Abernathy +3 more
doaj +1 more source
Experimental Systems for Measuring HIV Latency and Reactivation
Viruses, 2020 The final obstacle to achieving a cure to HIV/AIDS is the presence of latent HIV reservoirs scattered throughout the body. Although antiretroviral therapy maintains plasma viral loads below the levels of detection, upon cessation of therapy, the latent ...
Koh Fujinaga, Daniele C. Cary
doaj +1 more source
Viruses, 2022 Immune cell state alterations rewire HIV-1 gene expression, thereby influencing viral latency and reactivation, but the mechanisms are still unfolding.
Emily Cruz-Lorenzo +11 more
doaj +1 more source
Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. [PDF]
JCI Insight, 2018 HIV eradication studies have focused on developing latency-reversing agents (LRAs). However, it is not understood how the rate of latent reservoir reduction is affected by different steps in the process of latency reversal. Furthermore, as current LRAs are host-directed, LRA treatment is likely to be intermittent to avoid host toxicities.
Ke R +3 more
europepmc +4 more sources
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. [PDF]
Virology, 2018 HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with antiretroviral drugs alone. Latency reversing agents (LRAs) can activate HIV expression in latently infected cells, potentially leading to their elimination through virus-mediated cytopathic effects, host immune responses, and/or therapeutic strategies ...
Marsden MD +11 more
europepmc +5 more sources